Novartis: positive data for breast cancer drug
(CercleFinance.com) - Novartis has announced positive top-line results from an interim analysis of NATALEE, a phase III trial evaluating its Kisqali (ribociclib), in combination with hormone therapy, in early HR+/HER2- breast cancer at risk of recurrence.
The Swiss healthcare group says that the independent data monitoring committee recommended stopping the trial early because the primary endpoint of invasive disease-free survival was met.
Kisqali plus hormone therapy significantly reduced the risk of recurrence compared to standard hormone therapy alone in the adjuvant setting, with a consistent benefit in patients with early stage II and III breast cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The Swiss healthcare group says that the independent data monitoring committee recommended stopping the trial early because the primary endpoint of invasive disease-free survival was met.
Kisqali plus hormone therapy significantly reduced the risk of recurrence compared to standard hormone therapy alone in the adjuvant setting, with a consistent benefit in patients with early stage II and III breast cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.